Forgot Password?
Return to Course Listing

CME: Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Activity Description / Statement of Need:

In this online, self-learning activity:

Urothelial carcinoma (UC) is a cancer affecting both the bladder and beyond, including tumors of the upper urinary tract and proximal urethra. Cancers of the urinary tract affect more than 1.6 million people worldwide and collectively are the 6th most common type of cancer in the US. UC itself accounts for over 82,000 new cases and over 16,000 deaths each year. The five-year survival for noninvasive UC is 96% but drops to eight percent for metastatic disease (mUC), suggesting there may be room for improvement in the management of the disease.

Target Audience:

HCPs including: medical and genitourinary oncologist and urologist; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology and urology; and any other HCPs with an interest in or who clinically encounter patients with mUC.


Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

This activity is free of charge.


Release Date: August 24, 2024 -- Expiration Date: August 24, 2025

Faculty: Waddah Arafat, MD

Agenda

Faculty member introduction, disclosures, overview of  mUC

Major findings from ASCO 2024:

  • The Ultima trial for the management of urachal cancer.
  • Patient-related outcomes (PRO) from the EV-302 trial.
  • How the response to EV is impacted by upfront dose intensity and later dose reductions.
  • Checkmate 901 node-only CRs
  • NivoCisGem in node-only mUC patients.
  • Notable Posters

Patient cases

Concluding remarks

Learning Objectives

By the end of the session the participant will be able to:

  • Review the practice-changing Ultima trial for the management of urachal cancer.
  • Recall the patient-related outcomes (PRO) and quality-of-life (QoL) data from the EV-302 trial.
  • Describe how response to EV is impacted by upfront dose intensity and later dose reductions.
  • Review the response data of NivoCisGem in node-only mUC patients.
  • Apply the findings presented at ASCO to patient cases.

Accreditation

ACCME Activity #202808783

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for .075 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-24-022-H01-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Waddah Arafat, MD, Assistant Professor, Genitourinary Oncology, University of Texas Southwestern Medical Center, has received financial compensation from Seagen, Astellas, Exelixis, AstraZenca, Merck for grant/research support; in addition to consulting work for Cardinal Health (relationship has ended). 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Taking the next step in the management of relapsed or refractory follicular lymphoma

Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC)

Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape